Valuation: Ipsen

Market Cap 13.61B 15.18B 12.54B 11.39B 21.56B 1,423B 22.16B 150B 59.84B 762B 56.96B 55.75B 2,410B P/E 2026 *
12.8x
P/E 2027 * 13.4x
Enterprise Value 12.16B 13.56B 11.2B 10.17B 19.26B 1,271B 19.79B 134B 53.44B 681B 50.87B 49.79B 2,153B EV / Sales 2026 *
2.63x
EV / Sales 2027 * 2.31x
Free-Float
40.65%
Yield 2026 *
0.86%
Yield 2027 * 0.94%
1 day+1.59%
1 week+6.82%
Current month+5.33%
1 month+16.33%
3 months+2.72%
6 months-0.24%
Current year+39.50%
1 week 153.3
Extreme 153.3
167
1 month 141.6
Extreme 141.6
167
Current year 116
Extreme 116
174
1 year 115.6
Extreme 115.6
174
3 years 87.95
Extreme 87.95
174
5 years 77
Extreme 77
174
10 years 34.2
Extreme 34.2
174
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer 52 05/05/2023
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Buy

Director

500 0.0006%
8/9/26 Buy

Director

500 0.0006%
3/9/26 Sell

Director

-1,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%+6.82%+34.09%+53.70% 15.01B
+1.44%+1.51%+54.95%+142.22% 1,258B
-0.47%+3.78%+50.50%+90.46% 679B
+0.20%+1.75%+34.10%+112.90% 518B
+0.17%+1.16%+49.70%+68.75% 390B
-0.48%-0.21%+71.59%+44.61% 367B
+0.76%+2.25%+31.84%+59.53% 307B
-1.29%+0.17%+7.63%+33.04% 293B
0.00%-0.05%+45.29%+76.18% 252B
+0.92%+0.32%+43.78%+127.89% 210B
Average +0.21%+1.46%+42.35%+80.93% 429B
Weighted average by Cap. +0.07%+1.19%+46.60%+97.19%

Financials

2026 *2027 *
Net sales 4.62B 5.15B 4.25B 3.86B 7.31B 483B 7.52B 50.93B 20.29B 259B 19.32B 18.91B 817B 4.77B 5.32B 4.4B 3.99B 7.56B 499B 7.77B 52.65B 20.98B 267B 19.97B 19.55B 845B
Net income 1.14B 1.28B 1.05B 957M 1.81B 120B 1.86B 12.62B 5.03B 64.07B 4.79B 4.69B 203B 1.05B 1.17B 969M 880M 1.67B 110B 1.71B 11.61B 4.62B 58.92B 4.4B 4.31B 186B
Net Debt -1.45B -1.62B -1.34B -1.22B -2.3B -152B -2.37B -16.05B -6.39B -81.45B -6.09B -5.96B -257B -2.59B -2.89B -2.38B -2.17B -4.1B -270B -4.21B -28.55B -11.38B -145B -10.83B -10.6B -458B
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
10/11/26 €166.00 +1.59% 86,345
09/11/26 €163.40 +2.96% 126,910
06/11/26 €158.70 -0.44% 143,497
05/11/26 €159.40 +2.31% 128,668
04/11/26 €155.80 +1.70% 107,342
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
166.00EUR
Average target price
162.23EUR
Spread / Average Target
-2.27%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen